

Revised Draft Agenda
Biocides Working Group Meeting II-2021
1 – 11 June 2021

WG-II-2021 meetings are held as virtual meetings via WebEx

The time is indicated in Helsinki time.

Tuesday 1 June	10:00-17:00	APCP WG
Wednesday 2 June	10:00-17:00	APCP WG
Thursday 3 June	10:00-17:00	APCP WG
Tuesday 1 June	10:00-18:00	TOX WG
Wednesday 2 June	10:00-18:00	TOX WG
Tuesday 8 June	10:00-18:00	TOX WG
Wednesday 9 June	10:00-18:00	TOX WG
Thursday 10 June	10:30-18:00	TOX WG
Monday 7 June	14:00-18:00	EFF WG
Tuesday 8 June	10:00-18:00	EFF WG
Thursday 10 June	10:00-18:00	EFF WG
Friday 11 June	10:30-14:00	EFF WG
Thursday 3 June	10:00-14:00	ENV WG
Friday 4 June	10:00-17:00	ENV WG
Wednesday 9 June	10:00-18:00	ENV WG
Thursday 10 June	09:30-18:00	ENV WG
Friday 11 June	10:00-17:00	ENV WG

Analytical methods and physico-chemical properties Working Group		
Chair: Bernhard Krebs		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement on the minutes of WG I 2021		<i>For agreement</i>
Item 6 – Outcome of e-consultations (closed session)		
Item 7 - Discussion on Active Substances		eCA
7.1	1,2-Benzisothiazol-3(2H)-one (BIT) PT 06, 13 Meeting document: <i>WG II 2021_APCP_7-1</i>	ES <i>For agreement</i>
Item 8 - Discussions on Union Authorisations		eCA
8.1	UA for a product family containing hydrogen peroxide PT 02, 03, 04 (BC-WX029254-02) Meeting document: <i>WG II 2021_APCP_8-1</i>	FI <i>For agreement</i>
8.2	UA for a product containing hydrogen peroxide PT 02, 03, 04 (BC-ML029042-45) Meeting document: <i>WG II 2021_APCP_8-2</i>	NL <i>For agreement</i>
8.3	UA for a product family containing propan-2-ol PT 01, 02, 04 (BC-BL025673-43) Meeting document: <i>WG II 2021_APCP_8-3</i>	DE <i>For agreement</i>
8.4	UA for a product family containing propan-1-ol and propan-2-ol PT 01 (BC-MU051242-25) Meeting document: <i>WG II 2021_APCP_8-4</i>	CH <i>For agreement</i>

8.5	<p>UA for a product family containing propan-1-ol and propan-2-ol PT 01, 02, 04 (BC-AQ050985-22) Meeting document: <i>WG II 2021_APCP_8-5</i></p> <p style="text-align: right;"><i>For agreement</i></p>	CH
8.6	<p>UA for a product family containing active chlorine released from sodium hypochlorite PT 02, 03, 04, 05 (BC-MY047028-07) Meeting document: <i>WG II 2021_APCP_8-6</i></p> <p style="text-align: right;"><i>For agreement</i></p>	BE
8.7	<p>UA for a product containing Cyromazine PT 18 (BC-TH035808-24) Meeting document: <i>WG II 2021_APCP_8-7</i></p> <p style="text-align: right;"><i>For agreement</i></p>	CH
8.8	<p>UA for a product containing L-(+)-lactic acid PT 02 (BC-XS050968-91) Meeting document: <i>WG II 2021_APCP_8-8</i></p> <p style="text-align: right;"><i>For agreement</i></p>	LV
8.9	<p>UA for a product family containing active chlorine released from calcium hypochlorite PT 02, 04, 05 (BC-WK046289-14) Meeting document: <i>WG II 2021_APCP_8-9</i></p> <p style="text-align: right;"><i>For agreement</i></p>	FR
Item 9 – AoB		

Human Health Working Group		
Chair: Antero Airaksinen		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-I-2021		
<ul style="list-style-type: none"> • <i>WG-I-2021_TOX_6-1</i> • <i>WG-I-2021_TOX_6-2</i> • <i>WG-I-2021_TOX_7-1</i> • <i>WG-I-2021_TOX_7-2</i> • <i>WG-I-2021_TOX_7-3</i> • <i>WG-I-2021_TOX_8-1</i> • <i>WG-I-2021_TOX_9-2</i> • <i>WG-I-2021_TOX_9-3</i> • <i>WG-I-2021_TOX_9-4</i> • <i>WG-I-2021_TOX_Minutes</i> 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	1,2-Benzisothiazol-3(2H)-one (BIT) PT 6, 13 Meeting document: <i>WGII2021_TOX_6-1</i>	ES <i>For agreement</i>
6.2	DBNPA: Art 75(1)g request PT 4 Meeting document: <i>WGII2021_TOX_6-2</i>	DK <i>For discussion</i>
6.3	Cyanamide: Art 75(1)g request PT 3, 18 Meeting document: <i>WGII2021_TOX_6-3</i>	DE <i>For discussion</i>
6.4	Chlorhexidine: Early WG discussion PT 1, 2, 3 Meeting document: <i>WGII2021_TOX_6-4</i>	PT <i>For agreement</i>

Item 7 - Discussion of Union Authorisations		eCA
7.1	<p>UA for product containing L-(+)-lactic acid PT 02 (BC-XS050968-91) Meeting document: <i>WGII2021_TOX_7-1</i></p> <p style="text-align: right;"><i>For agreement</i></p>	LV
7.2	<p>UA for product family containing 1-propanol / 2-propanol PT 01 (BC-MU051242-25) Meeting document: <i>WGII2021_TOX_7-2</i></p> <p style="text-align: right;"><i>For agreement</i></p>	CH
7.3	<p>UA for product family containing 1-propanol / 2-propanol PT 01, 02, 04 (BC-AQ050985-22) Meeting document: <i>WGII2021_TOX_7-3</i></p> <p style="text-align: right;"><i>For agreement</i></p>	CH
7.4	<p>UA for product family containing active chlorine released from sodium hypochlorite PT 02, 03, 04, 05 (BBC-MY047028-07) Meeting document: <i>WGII2021_TOX_7-4</i></p> <p style="text-align: right;"><i>For agreement</i></p>	BE
7.5	<p>UA for product family containing active chlorine released from calcium hypochlorite PT 02, 04, 05 (BC-WK046289-14) Meeting document: <i>WGII2021_TOX_7-5</i></p> <p style="text-align: right;"><i>For agreement</i></p>	FR
7.6	<p>UA for product containing cyromazine PT 18 (BC-TH035808-24) Meeting document: <i>WGII2021_TOX_7-6</i></p> <p style="text-align: right;"><i>For agreement</i></p>	CH
7.7	<p>UA for product family containing hydrogen peroxide PT 02, 03, 04 (BC-WX029254-02) Meeting document: <i>WGII2021_TOX_7-7</i></p> <p style="text-align: right;"><i>For agreement</i></p>	FI
7.8	<p>UA for product containing hydrogen peroxide PT 02, 03, 04 (BC-ML029042-45) Meeting document: <i>WGII2021_TOX_7-8</i></p> <p style="text-align: right;"><i>For agreement</i></p>	NL
7.9	<p>UA for product family containing propan-2-ol PT 01, 02, 04 (BC-BL025673-43) Meeting document: <i>WGII2021_TOX_7-9</i></p> <p style="text-align: right;"><i>For agreement</i></p>	DE

Item 8 - Technical and guidance related issues		Presenter
8.1	Update on guidance development Meeting document: <i>WGII2021_TOX_8-1</i> <i>For discussion</i>	SECR
Item 9 – AOB		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGII2021_TOX_9-1</i> <i>For discussion</i>	SECR

Environment Working Group		
Chair: Heike Schimmelpfennig		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes of WG-I-2021		
<ul style="list-style-type: none"> • <i>WG-I-2021_ENV_6-1</i> • <i>WG-I-2021_ENV_6-2 updated</i> • <i>WG-I-2021_ENV_7-1</i> • <i>WG-I-2021_ENV_7-2 updated</i> • <i>WG-I-2021_ENV_7-3</i> • <i>WG-I-2021_ENV_7-4</i> • <i>WG-I-2021_ENV_General minutes updated</i> 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	DBNPA: Art 75(1)g request PT 4 Meeting document: <i>WGII2021_ENV_6-1</i>	DK
<i>For discussion</i>		
6.2	Cyanamide: Art 75(1)g request PT 3, 18 Meeting document: <i>WGII2021_ENV_6-2</i>	DE
<i>For discussion</i>		
6.3	1,2-Benzisothiazol-3(2H)-one (BIT) PT 06, 13 Meeting document: <i>WGII2021_ENV_6-3</i>	ES
<i>For agreement</i>		
Item 7 - Discussion of Union Authorisations		eCA

7.1	UA for product containing L-(+)-lactic acid PT 02 (BC-XS050968-91) Meeting document: <i>WGII2021_ENV_7-1</i> <i>For agreement</i>	LV
7.2	UA for product family containing 1-propanol / 2-propanol PT 01 (BC-MU051242-25) Meeting document: <i>WGII2021_ENV_7-2</i> <i>For agreement</i>	CH
7.3	UA for product family containing 1-propanol / 2-propanol PT 01, 02, 04 (BC-AQ050985-22) Meeting document: <i>WGII2021_ENV_7-3</i> <i>For agreement</i>	CH
7.4	UA for product family containing active chlorine released from sodium hypochlorite PT 02, 03, 04, 05 (BBC-MY047028-07) Meeting document: <i>WGII2021_ENV_7-4</i> <i>For agreement</i>	BE
7.5	UA for product family containing active chlorine released from calcium hypochlorite PT 02, 04, 05 (BC-WK046289-14) Meeting document: <i>WGII2021_ENV_7-5</i> <i>For agreement</i>	FR
7.6	UA for product containing cyromazine PT 18 (BC-TH035808-24) Meeting document: <i>WGII2021_ENV_7-6</i> <i>For agreement</i>	CH
7.7	UA for product family containing hydrogen peroxide PT 02, 03, 04 (BC-WX029254-02) Meeting document: <i>WGII2021_ENV_7-7</i> <i>For agreement</i>	FI
7.8	UA for product containing hydrogen peroxide PT 02, 03, 04 (BC-ML029042-45) Meeting document: <i>WGII2021_ENV_7-8</i> <i>For agreement</i>	NL
7.9	UA for product family containing propan-2-ol PT 01, 02, 04 (BC-BL025673-43) Meeting document: <i>WGII2021_ENV_7-9</i> <i>For agreement</i>	DE

Item 8 – AOB

8.1	Chesar platform: Core scenario development for PT 3 & PT 18 Meeting document: <i>WGII2021_ENV_8-1</i> <i>For agreement</i>	DE, SECR
8.2	Disinfection by-products Meeting document: <i>WGII2021_ENV_8-2</i> <i>For discussion</i>	FR
8.3	Other information & lessons learned SECR to inform <i>For information</i>	SECR

Efficacy Working Group		
Chair: Katarzyna Szymankiewicz		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-I-2021		
<ul style="list-style-type: none"> • <i>WG-I-2021_EFF_6-1</i> • <i>WG-I-2021_EFF_7-1</i> • <i>WG-I-2021_EFF_7-2</i> • <i>WG-I-2021_EFF_7-3</i> • <i>WG-I-2021_EFF_7-4</i> • <i>WG-I-2021_EFF_Minutes</i> 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	1,2-Benzisothiazol-3(2H)-one (BIT) PT 06, 13 Meeting document: <i>WGII2021_EFF_6-1</i>	ES <i>For agreement</i>
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for product containing L-(+)-lactic acid PT 02 (BC-XS050968-91) Meeting document: <i>WGII2021_EFF_7-1</i>	LV <i>For agreement</i>
7.2	UA for product family containing 1-propanol / 2-propanol PT 01 (BC-MU051242-25) Meeting document: <i>WGII2021_EFF_7-2</i>	CH <i>For agreement</i>
7.3	UA for product family containing 1-propanol / 2-propanol PT 01, 02, 04 (BC-AQ050985-22) Meeting document: <i>WGII2021_EFF_7-3</i>	CH <i>For agreement</i>

7.4	UA for product family containing active chlorine released from sodium hypochlorite PT 02, 03, 04, 05 (BBC-MY047028-07) Meeting document: <i>WGII2021_EFF_7-4</i> <i>For agreement</i>	BE
7.5	UA for product family containing active chlorine released from calcium hypochlorite PT 02, 04, 05 (BC-WK046289-14) Meeting document: <i>WGII2021_EFF_7-5</i> <i>For agreement</i>	FR
7.6	UA for product containing cyromazine PT 18 (BC-TH035808-24) Meeting document: <i>WGII2021_EFF_7-6</i> <i>For agreement</i>	CH
7.7	UA for product family containing hydrogen peroxide PT 02, 03, 04 (BC-WX029254-02) Meeting document: <i>WGII2021_EFF_7-7</i> <i>For agreement</i>	FI
7.8	UA for product containing hydrogen peroxide PT 02, 03, 04 (BC-ML029042-45) Meeting document: <i>WGII2021_EFF_7-8</i> <i>For agreement</i>	NL
7.9	UA for product family containing propan-2-ol PT 01, 02, 04 (BC-BL025673-43) Meeting document: <i>WGII2021_EFF_7-9</i> <i>For agreement</i>	DE
Item 8 – AOB		
8.1	Other information & lessons learned Meeting document: <i>WGII2021_EFF_8-1</i> <i>For information</i>	ECHA